{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:04:21Z","timestamp":1790885061659,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Equity Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In September 2019, the \u201c4\u2009+\u20097\u201d centralized procurement pilot program was expanded nationwide aiming at reducing drug prices by means of volume-based procurement and using accredited generic drugs for branded drug substitutes. Given the current uncertain effect of the policy outside pilot areas, this study was conducted to evaluate the impact of the National Volume-based Procurement policy on the use of policy-related drugs after expansion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>A single-group interrupted time series was applied using drug purchase data, covering 25\u00a0months from December 2018 to December 2020. Drugs related to the centralized procurement policy were selected as samples, including 25 first-batch policy-related drugs and 56 alternative drugs. Centralized procured drugs can be divided into bid-winning and non-winning products, where non-winning products were sorted into generic and branded drugs, and alternative products were classified according to different degrees of substitution. Purchase volume, expenditures, and daily costs were measured.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After the implementation of the policy, a significant increase was associated with the volume of bid-winning drugs (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and the volume of generic and branded drugs decreased immediately. The DDDc of drugs under the same generic name significantly reduced (an instantaneous drop of bid-winning drugs by approximately 25%, 7.62 CNY for generics and 3.07 CNY for branded drugs), saving 48.2 million CNY of drug expenditures. The policy has a significant effect on the drug for the treatment of cardiovascular diseases and exerted little influence on the drug for the treatment of nervous diseases, and the substitution of generics for antitumor-branded drugs was not obvious. In addition, the procurement volume of alternative drugs appeared to be a \u201ccarry-over\u201d.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These findings indicated that the policy demonstrated positive effects in terms of price reductions and cost savings and accelerated the substitution of generics against branded drugs. The \u201cpatent cliff\u201d for branded drugs has gradually emerged. Besides, a short-term \u201cspillover effect\u201d of the volume of alternative drugs was observed, requiring special attention and vigilance.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12939-023-02006-1","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T14:02:24Z","timestamp":1695909744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Xiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengdie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouli","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"2006_CR1","doi-asserted-by":"crossref","unstructured":"Chen C, Liu M. Achievements and Challenges of the Healthcare System in China. Cureus. 2023;15(5):e39030.","DOI":"10.7759\/cureus.39030"},{"key":"2006_CR2","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S0140-6736(19)32136-1","volume":"394","author":"W Yip","year":"2019","unstructured":"Yip W, Fu H, Chen AT, Zhai T, Jian W, Xu R, Pan J, Hu M, Zhou Z, Chen Q, et al. 10 years of health-care reform in China: progress and gaps in Universal Health Coverage. Lancet. 2019;394:1192\u2013204.","journal-title":"Lancet"},{"key":"2006_CR3","first-page":"1","volume":"29","author":"ChinaNHCotPsRo","year":"2022","unstructured":"ChinaNHCotPsRo. Statistical bulletin of China\u2019s health development in 2021(Article in Chinese). Chin Pract J Rural Doctor. 2022;29:1\u201311.","journal-title":"Chin Pract J Rural Doctor"},{"key":"2006_CR4","unstructured":"National Health Commission of the People\u2019s Republic of China. China health statistics Yearbook 2021. Beijing: Peking Union Medical College Press: National Health Commission of the People\u2019s Republic of China; 2021."},{"issue":"9","key":"2006_CR5","doi-asserted-by":"publisher","first-page":"e005519","DOI":"10.1136\/bmjgh-2021-005519","volume":"6","author":"J Yuan","year":"2021","unstructured":"Yuan J, Lu ZK, Xiong X, Jiang B. Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China. BMJ Glob Health. 2021;6(9):e005519.","journal-title":"BMJ Glob Health"},{"key":"2006_CR6","unstructured":"Pilot Program for National Centralized Drug Procurement and Use. http:\/\/www.gov.cn\/zhengce\/content\/2019-01\/17\/content_5358604.htm."},{"key":"2006_CR7","unstructured":"Evaluation Scheme of Generic Quality Consistency. https:\/\/www.nmpa.gov.cn\/zhuanti\/ypqxgg\/ggzhcfg\/20130216144301515.html."},{"key":"2006_CR8","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1186\/s12913-021-07143-3","volume":"21","author":"Y Yang","year":"2021","unstructured":"Yang Y, Tong R, Yin S, Mao L, Xu L, Hao S, Mao Z. The impact of \u201c4 + 7\u201d volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis. BMC Health Serv Res. 2021;21:1275.","journal-title":"BMC Health Serv Res"},{"key":"2006_CR9","doi-asserted-by":"publisher","first-page":"923209","DOI":"10.3389\/fphar.2022.923209","volume":"13","author":"J Lu","year":"2022","unstructured":"Lu J, Long H, Shen Y, Wang J, Geng X, Yang Y, Mao Z, Li J. The change of drug utilization in China\u2019s public healthcare institutions under the \u201c4 + 7\u201d centralized drug procurement policy: Evidence from a natural experiment in China. Front Pharmacol. 2022;13:923209.","journal-title":"Front Pharmacol"},{"key":"2006_CR10","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1002\/hpm.3429","volume":"37","author":"Y Yang","year":"2022","unstructured":"Yang Y, Hu R, Geng X, Mao L, Wen X, Wang Z, Hao S, Cui D, Mao Z. The impact of National Centralised Drug Procurement policy on the use of policy-related original and generic drugs in China. Int J Health Plann Manage. 2022;37:1650\u201362.","journal-title":"Int J Health Plann Manage"},{"key":"2006_CR11","unstructured":"Notice of the National Healthcare Security Administration on Issuing the Catalogue of National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drugs. 2022. http:\/\/www.nhsa.gov.cn\/art\/2023\/1\/18\/art_104_10078.html."},{"key":"2006_CR12","doi-asserted-by":"publisher","first-page":"944540","DOI":"10.3389\/fphar.2022.944540","volume":"13","author":"H Long","year":"2022","unstructured":"Long H, Yang Y, Geng X, Mao Z, Mao Z. Changing characteristics of pharmaceutical prices in china under centralized procurement policy: a multi-intervention interrupted time series. Front Pharmacol. 2022;13:944540.","journal-title":"Front Pharmacol"},{"key":"2006_CR13","doi-asserted-by":"publisher","first-page":"e054346","DOI":"10.1136\/bmjopen-2021-054346","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, Yang Y, Xu L, Shen Y, Wen X, Mao L, Wang Q, Cui D, Mao Z. Impact of \u201c4+7\u201d volume-based drug procurement on the use of policy-related original and generic drugs: a natural experimental study in China. BMJ Open. 2022;12:e054346.","journal-title":"BMJ Open"},{"key":"2006_CR14","unstructured":"Hospital drug use monitoring report (the first half of 2020). https:\/\/www.cpa.org.cn\/\/?do=\u4fe1\u606f&cid=75541."},{"key":"2006_CR15","unstructured":"Notice on Reference Monitoring Scope of Substitutable Drugs of National Centralized Drug Procurement. http:\/\/www.cqfj.gov.cn\/index\/bm_168\/ylbzj\/zwgk_61851\/fdzdgknr_61853\/lzyj_61854\/qtgw_61856\/202211\/W020221103593297618630.pdf."},{"key":"2006_CR16","unstructured":"ATC\/DDD Index 2023. https:\/\/www.whocc.no\/atc_ddd_index\/."},{"key":"2006_CR17","volume-title":"New Pharmacology","author":"C Xinqian","year":"2018","unstructured":"Xinqian C. New Pharmacology. 18th ed. Beijing: Beijing: people\u2019s medical publishing; 2018.","edition":"18"},{"issue":"24","key":"2006_CR18","doi-asserted-by":"publisher","first-page":"9415","DOI":"10.3390\/ijerph17249415","volume":"17","author":"L Chen","year":"2020","unstructured":"Chen L, Yang Y, Luo M, Hu B, Yin S, Mao Z. The impacts of national centralized drug procurement policy on drug utilization and drug expenditures: the case of Shenzhen, China. Int J Environ Res Public Health. 2020;17(24):9415.","journal-title":"Int J Environ Res Public Health"},{"key":"2006_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pec.2013.12.003","volume":"95","author":"Z Xiao","year":"2014","unstructured":"Xiao Z, Xu F. Health literacy and medication preference: why do most patients choose imported brand-name drugs? Patient Educ Couns. 2014;95:155\u20136.","journal-title":"Patient Educ Couns"},{"key":"2006_CR20","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1080\/14034940600551111","volume":"34","author":"K Andersson","year":"2006","unstructured":"Andersson K, Jorgensen T, Carlsten A. Physicians\u2019 opinions and experiences of the Pharmaceutical Benefits Reform. Scand J Public Health. 2006;34:654\u20139.","journal-title":"Scand J Public Health"},{"key":"2006_CR21","unstructured":"2018: A year of advancing generic products and policies, laying the foundation for 2019. https:\/\/www.fda.gov\/news-events\/fda-voices\/2018-year-advancing-generic-products-and-policies-laying-foundation-2019."},{"key":"2006_CR22","unstructured":"Promoting the Use of Generic Drugs. http:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/kenkou_iryou\/iryou\/kouhatu-iyaku\/index.html."},{"issue":"10","key":"2006_CR23","doi-asserted-by":"publisher","first-page":"e003891","DOI":"10.1161\/CIRCOUTCOMES.117.003891","volume":"10","author":"J Leclerc","year":"2017","unstructured":"Leclerc J, Blais C, Rochette L, Hamel D, Guenette L, Poirier P. Impact of the commercialization of three generic angiotensin II receptor blockers on adverse events in Quebec, Canada: a population-based time series analysis. Circ Cardiovasc Qual Outcomes. 2017;10(10):e003891.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2006_CR24","volume-title":"Management Sciences for Health","author":"A Barraclough","year":"2012","unstructured":"Barraclough A, Clark M. Chapter 18: managing procurement. In: Management Sciences for Health. Arlington (VA): Management Sciences for Health; 2012."},{"issue":"Suppl 5","key":"2006_CR25","doi-asserted-by":"publisher","first-page":"v29","DOI":"10.1093\/annonc\/mdt326","volume":"24","author":"L Renner","year":"2013","unstructured":"Renner L, Nkansah FA, Dodoo AN. The role of generic medicines and biosimilars in oncology in low-income countries. Ann Oncol. 2013;24(Suppl 5):v29-32.","journal-title":"Ann Oncol"},{"key":"2006_CR26","doi-asserted-by":"publisher","first-page":"e000243","DOI":"10.1136\/bmjgh-2016-000243","volume":"2","author":"G Seidman","year":"2017","unstructured":"Seidman G, Atun R. Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries. BMJ Glob Health. 2017;2:e000243.","journal-title":"BMJ Glob Health"},{"key":"2006_CR27","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/heapol\/czi015","volume":"20","author":"RR Chaudhury","year":"2005","unstructured":"Chaudhury RR, Parameswar R, Gupta U, Sharma S, Tekur U, Bapna JS. Quality medicines for the poor: experience of the Delhi programme on rational use of drugs. Health Policy Plan. 2005;20:124\u201336.","journal-title":"Health Policy Plan"},{"key":"2006_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/heapol\/czs015","volume":"28","author":"A Adesina","year":"2013","unstructured":"Adesina A, Wirtz VJ, Dratler S. Reforming antiretroviral price negotiations and public procurement: the Mexican experience. Health Policy Plan. 2013;28:1\u201310.","journal-title":"Health Policy Plan"},{"key":"2006_CR29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/hec.3013","volume":"24","author":"PM Danzon","year":"2015","unstructured":"Danzon PM, Mulcahy AW, Towse AK. Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement. Health Econ. 2015;24:238\u201352.","journal-title":"Health Econ"},{"key":"2006_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1053\/j.seminoncol.2021.03.001","volume":"48","author":"Z Luo","year":"2021","unstructured":"Luo Z, Gyawali B, Han S, Shi L, Guan X, Wagner AK. Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China. Semin Oncol. 2021;48:141\u20134.","journal-title":"Semin Oncol"},{"key":"2006_CR31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40263-013-0045-2","volume":"27","author":"M Carbon","year":"2013","unstructured":"Carbon M, Correll CU. Rational use of generic psychotropic drugs. CNS Drugs. 2013;27:353\u201365.","journal-title":"CNS Drugs"},{"key":"2006_CR32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10198-012-0377-8","volume":"13","author":"MI Farfan-Portet","year":"2012","unstructured":"Farfan-Portet MI, Van de Voorde C, Vrijens F, Vander Stichele R. Patient socioeconomic determinants of the choice of generic versus brand name drugs in the context of a reference price system: evidence from Belgian prescription data. Eur J Health Econ. 2012;13:301\u201313.","journal-title":"Eur J Health Econ"},{"key":"2006_CR33","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.sapharm.2017.08.001","volume":"14","author":"JN Howard","year":"2018","unstructured":"Howard JN, Harris I, Frank G, Kiptanui Z, Qian J, Hansen R. Influencers of generic drug utilization: a systematic review. Res Social Adm Pharm. 2018;14:619\u201327.","journal-title":"Res Social Adm Pharm"},{"issue":"Suppl 1","key":"2006_CR34","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1111\/j.1524-4733.2008.00376.x","volume":"11","author":"Y Chen","year":"2008","unstructured":"Chen Y, Schweitzer SO. Issues in drug pricing, reimbursement, and access in China with references to other Asia-Pacific region. Value Health. 2008;11(Suppl 1):S124-129.","journal-title":"Value Health"},{"key":"2006_CR35","doi-asserted-by":"publisher","first-page":"11016","DOI":"10.7189\/jogh.12.11016","volume":"12","author":"L Cai","year":"2022","unstructured":"Cai L, Tao T, Li H, Zhang Z, Zhang L, Li X. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: a controlled interrupted time series study. J Glob Health. 2022;12:11016.","journal-title":"J Glob Health"},{"key":"2006_CR36","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1186\/s12913-021-06698-5","volume":"21","author":"Y Yang","year":"2021","unstructured":"Yang Y, Chen L, Ke X, Mao Z, Zheng B. The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018\u20132019: an interrupted time-series analysis. BMC Health Serv Res. 2021;21:668.","journal-title":"BMC Health Serv Res"},{"key":"2006_CR37","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/ijpp.12299","volume":"25","author":"E Olsson","year":"2017","unstructured":"Olsson E, Wallach-Kildemoes H, Ahmed B, Ingman P, Kaae S, K\u00e4lvemark Sporrong S. The influence of generic substitution on the content of patient\u2013pharmacist communication in Swedish community pharmacies. Int J Pharm Pract. 2017;25:274\u201381.","journal-title":"Int J Pharm Pract"},{"key":"2006_CR38","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.2042-7174.2012.00214.x","volume":"20","author":"E Olsson","year":"2012","unstructured":"Olsson E, K\u00e4lvemark Sporrong S. Pharmacists\u2019 experiences and attitudes regarding generic drugs and generic substitution: two sides of the coin. Int J Pharm Pract. 2012;20:377\u201383.","journal-title":"Int J Pharm Pract"}],"container-title":["International Journal for Equity in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12939-023-02006-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12939-023-02006-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12939-023-02006-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T08:18:56Z","timestamp":1700381936000},"score":1,"resource":{"primary":{"URL":"https:\/\/equityhealthj.biomedcentral.com\/articles\/10.1186\/s12939-023-02006-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2006"],"URL":"https:\/\/doi.org\/10.1186\/s12939-023-02006-1","relation":{},"ISSN":["1475-9276"],"issn-type":[{"value":"1475-9276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]},"assertion":[{"value":"21 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"200"}}